Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21095946 | 0.98 | PDE9A (0.35) | PDE9AKDM1AGPR3ALOX5APFEN1 | |
| SCHEMBL15488938 | 0.95 | PDE9A (0.39) | PDE9AKDM1AALDH1A1GLAGAA | |
| SCHEMBL21095839 | 0.93 | AR (0.39) | PDE9AKDM1AALOX5APFEN1NCOA1 | |
| SCHEMBL20813274 | 0.88 | GPR3 (0.32) | GPR3ALOX5APFEN1 | |
| SCHEMBL14767337 | 0.86 | AR (0.40) | KDM1APOLBALDH1A1GLAGAA | |
| SCHEMBL14226556 | 0.86 | GPR3 (0.35) | GPR3ALOX5APFEN1 | |
| SCHEMBL14681250 | 0.86 | GPR3 (0.35) | GPR3ALOX5APFEN1 | |
| SCHEMBL12889476 | 0.86 | GPR3 (0.35) | GPR3ALOX5APFEN1 | |
| SCHEMBL20802456 | 0.86 | GPR3 (0.30) | GPR3 | |
| SCHEMBL21095848 | 0.86 | KIF11 (0.36) | PDE9AKDM1AALOX5APFEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10982149-B2 | Chiral compounds | MERCK PATENT GMBH (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10450509-B2 | Liquid crystal medium and liquid display | MERCK PATENT GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-20180223189-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180223189-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9938464-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9822305-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-9809749-B2 | Mesogenic compound, liquid-crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9809749-B2 | Mesogenic compound, liquid-crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-20170226422-A1 | POLYMERISABLE MESOGENIC COMPOUND, LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170002290-A1 | ELECTRO-RHEOLOGICAL FLUID AND HAPTIC DEVICE | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
| US-20150247089-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-09-03 | — | — | US | disclosed |
| US-9120969-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9120969-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-20150129800-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20140158934-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140077130-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-20140077130-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-8659737-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| WO-2013034219-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10982149-B2 | Chiral compounds | FANCI, COL1A1, LCP1 | PDE9A 1731/4885KDM1A 1596/4885GPR3 2116/4885 |
| US-10450509-B2 | Liquid crystal medium and liquid display | NEFM, CRY1, BMP2 | PDE9A 878/4885KDM1A 4562/4885GPR3 3519/4885 |
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | BMP2, IK, EML4 | PDE9A 2275/4885KDM1A 4243/4885GPR3 3750/4885 |
| US-20150129800-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | CCND2, CFD, CRY1 | PDE9A 779/4885KDM1A 4060/4885GPR3 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.